Last reviewed · How we verify

Meptin® Swinghaler

Taiwan Otsuka Pharm. Co., Ltd · Phase 3 active Small molecule

Meptin is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in respiratory conditions.

Meptin is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in respiratory conditions. Used for Asthma, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameMeptin® Swinghaler
Also known asMeptin® Swinghaler®, Procaterol HCL, Ventolin® MDI, Salbutamol sulfate
SponsorTaiwan Otsuka Pharm. Co., Ltd
Drug classBeta-2 adrenergic agonist (short-acting or long-acting bronchodilator)
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

The drug binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering intracellular signaling that leads to muscle relaxation and bronchodilation. This increases airway diameter and improves airflow, providing symptomatic relief in obstructive airway diseases. The Swinghaler formulation is an inhalation device designed for convenient drug delivery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: